In this subgroup analysis, treatment with rozanolixizumab demonstrated improvements from baseline in multiple MG-specific endpoints in patients with MuSK Ab+ gMG, consistent with those observed in the overall population. This evidence concerns the gene MUSK and myasthenia gravis.